Clinical trials: Malignant Neoplasm of Prostate
Malignant Glioma, Hepatocellular Carcinoma
Early-Phase Safety of Proton Therapy Equipment
The main purpose of this study is to collect the safety data of Sumitomo Heavy Industries' proton therapy equipment for the treatment of solid cancer patients in Linkou Chang Gung Memorial Hospital, including the patients'…
- Conditions
- Malignant Glioma, Hepatocellular Carcinoma, Head and Neck Malignant Tumor, Prostate Cancer
- Trial name
- NCT02315989
- Testing
- proton therapy
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Chang Gung Memorial Hospital
Prostate Adenocarcinoma
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
The primary objective of this study is to document the effectiveness of Cyberknife stereotactic body radiotherapy (SBRT) in the treatment of intermediate and high-risk localized prostate cancer defined by biochemical Disease-Free…
- Trial name
- NCT01985828
- Testing
- CyberKnife, Androgen Deprivation Therapy (ADT), Intensity Modulated radiation therapy (IMRT)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Wake Forest University Health Sciences
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
EXERCISING TOGETHER for Couples Coping With Cancer
The Exercising Together trial is a single-blind, parallel group, randomized controlled trial comparing 3 arms: Arm 1 (experimental): Exercising Together where couples perform partnered exercise in a supervised, group setting…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma
- Trial name
- NCT03630354
- Testing
- Exercise Intervention (supervised), Exercise Intervention (unsupervised), Informational Intervention
- Where
- United States
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Advanced/Metastatic Solid Tumor
KZR-261 in Subjects With Advanced Solid Malignancies
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase…
- Trial name
- NCT05047536
- Testing
- KZR-261
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Kezar Life Sciences, Inc.
Cancer
Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
This study is for patients who have a high risk of metastatic prostate cancer (cancer that has spread outside of the prostate) who are going to have radical prostatectomy.
- Trial name
- EDRN-FACBC (NCT03081884)
- Testing
- FACBC PET-CT Imaging
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Emory University
Metastasis From Malignant Tumor of Prostate (Disorder)
Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
This is a prospective, open-label Phase 2 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent metastatic prostate cancer after radical prostatectomy or radiation therapy.
- Trial name
- NCT05653856
- Testing
- 64Cu-PSMA I&T
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Curium US LLC
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Malignant Melanoma, Medullary Thyroid Cancer
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
- Conditions
- Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma
- Trial name
- NCT02709889
- Testing
- Rovalpituzumab tesirine, Dexamethasone
- Where
- 30 sites in United States
- Volunteers
- 200 people
- Sponsor
- AbbVie
Prostate Cancer, Prostate Adenocarcinoma
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
The purpose of this study is to determine what the safest dose of talazoparib plus temozolomide for participants with metastatic castration resistant prostate cancer.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic
- Trial name
- NCT04019327
- Testing
- Talazoparib, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
The goal of this clinical research study is to find out if a therapy using docetaxel chemotherapy with hormonal therapy taken before your scheduled surgery is beneficial to treatment of prostate cancer.
- Trial name
- NCT01076335
- Testing
- Neoadjuvant Hormonal Therapy, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Castration Resistant Prostate Cancer
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
The purpose of the study was to understand if there is benefit in treatment with a medicine called enzalutamide in the re-treatment setting.
- Trial name
- NCT02441517
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer, Prostate Cancer Metastatic
MSG Use With 18F-DCFPyL PET/CT Imaging
18F-DCFPyL is an agent that binds to prostate specific membrane antigen (PSMA). Due to high levels of PSMA in prostate cancer, treatments targeting PSMA have been developed to deliver therapy to these specific target cells.
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostatic Neoplasm
- Trial name
- NCT03693742
- Testing
- 18F-DCFPyL PET/CT scan, MSG drink
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer.
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03649841
- Testing
- Antiandrogen Therapy, Abiraterone Acetate, Prednisone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Washington
Prostate Cancer, Metastatic (Spread to Other Areas of the Body)
BKM120 in Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the effects of the study drug, BKM120. The study drug, BKM120, is an inhibitor of a protein called phosphatidyl inositol-3-kinase (PI3K).
- Trial name
- NCT01385293
- Testing
- BKM120
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Andrew J. Armstrong, MD
Prostate Cancer, Neoplasm Metastasis
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Multicenter study in which patients with metastatic hormone refractory prostate cancer (HRPC), who have not had previous chemotherapy or immunotherapy treatments, received MDX-010 every 3 weeks for 4 doses (12 weeks total…
- Trial name
- NCT00323882
- Testing
- MDX-010
- Where
- 14 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Prostatic Neoplasms, Castration-Resistant
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
The primary objective was to confirm the effect of tasquinimod in delaying disease progression or death as compared with placebo in chemo-naïve patients with metastatic castrate-resistant prostate cancer (mCRPC).
- Trial name
- TasQ003 (NCT02057666)
- Testing
- Tasquinimod
- Where
- 36 sites in China, South Korea and 1 more
- Volunteers
- 146 people
- Sponsor
- Ipsen
Castration-resistant Prostate Cancer, Metastasis
Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
The investigators propose a phase II study to evaluate the efficacy of carboplatin monotherapy in the tumor subgroup of metastatic castration-resistant prostatic carcinomas with somatic abnormality in the Homologous Recombination…
- Trial name
- PRO-CARBO (NCT03652493)
- Testing
- Carboplatin
- Where
- 4 sites in France
- Volunteers
- 16 people
- Sponsor
- Centre Francois Baclesse
Metastatic Cancer, Prostate Cancer
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
RATIONALE: Diagnostic procedures, such as radionuclide imaging using calcium-41 (41Ca) chloride aqueous solution, may help predict progressive disease in patients with prostate cancer and bone metastasis.
- Trial name
- UCDCC#217 (NCT00918645)
- Testing
- 41 Ca
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of California, Davis
Breast Carcinoma, Colorectal Carcinoma
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
This clinical trial studies the effectiveness of a web-based cancer education tool called Helping Oncology Patients Explore Genomics (HOPE-Genomics) in improving patient knowledge of personal genomic testing results and cancer…
- Conditions
- Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT04905082
- Testing
- Best Practice, Educational Intervention, Genomic Profile
- Where
- United States
- Volunteers
- 465 people
- Sponsor
- City of Hope Medical Center